Gossamer Bio Business Summary

Gossamer Bio, Inc. (GOSS) is a late-stage clinical biopharmaceutical company that generates revenue primarily through strategic global collaboration agreements, most notably its 2024 partnership with the Chiesi Group for the development and commercialization of its lead candidate, seralutinib. The company’s business model focuses on the discovery and clinical advancement of novel therapeutics for immunology, inflammation, and oncology, with its primary segment dedicated to pulmonary hypertension (PH), including pulmonary arterial hypertension (PAH) and PH associated with interstitial lung disease (PH-ILD). As of February 2026, Gossamer is at a critical inflection point awaiting Phase 3 PROSERA trial results, positioning itself as a developer of potentially disease-modifying inhaled therapies that can be used in combination with existing standards of care. Its direct competitors include established players and clinical rivals such as United Therapeutics, Merck (following its acquisition of Acceleron), Aerovate Therapeutics, and Tenax Therapeutics, against whom Gossamer competes by targeting the underlying cellular remodeling of pulmonary vasculature. The company was co-founded by Faheem Hasnain and Dr. Sheila Gujrathi, both of whom previously led Receptos to a multi-billion dollar acquisition by Celgene. The current leadership team is headed by Faheem Hasnain, who serves as Chairman and CEO, bringing extensive pedigree from executive roles at Facet Biotech, Biogen, and Bristol-Myers Squibb. He is supported by Bryan Giraudo, who serves as both Chief Operating Officer and Chief Financial Officer with a background in healthcare investment banking at Leerink Partners, and Dr. Richard Aranda, the Chief Medical Officer, who previously oversaw clinical development at Receptos. Gossamer’s strategic direction is further guided by a board featuring industry veterans like Lead Independent Director Dr. Thomas Daniel and Dr. Sandra Milligan. The firm is backed by prominent life science investors, including Arch Venture Partners, Hillhouse Capital, and Omega Funds, maintaining a robust institutional ownership base that includes Lazard and AQR Capital Management.